PlainRecalls
FDA Drug Moderate Class II Ongoing

Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day, 50/140 Twice Weekly, Rx Only a) 2 Systems NDC 68968-0514-2 b) 8 Systems NDC 68968-0514-8, Mfd. by: Noven Pharmaceuticals, Inc., Miami, Florida 33186, Dist. by: Noven Therapeutics LLC, Miami, Florida 33186

Reported: August 25, 2021 Initiated: July 30, 2021 #D-0724-2021

Product Description

Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day, 50/140 Twice Weekly, Rx Only a) 2 Systems NDC 68968-0514-2 b) 8 Systems NDC 68968-0514-8, Mfd. by: Noven Pharmaceuticals, Inc., Miami, Florida 33186, Dist. by: Noven Therapeutics LLC, Miami, Florida 33186

Reason for Recall

Failed Stability Specifications; out of specification for shear.

Details

Recalling Firm
Noven Pharmaceuticals Inc
Units Affected
223,382 boxes
Distribution
Nationwide.
Location
Miami, FL

Frequently Asked Questions

What product was recalled?
Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.14 mg per day, 50/140 Twice Weekly, Rx Only a) 2 Systems NDC 68968-0514-2 b) 8 Systems NDC 68968-0514-8, Mfd. by: Noven Pharmaceuticals, Inc., Miami, Florida 33186, Dist. by: Noven Therapeutics LLC, Miami, Florida 33186. Recalled by Noven Pharmaceuticals Inc. Units affected: 223,382 boxes.
Why was this product recalled?
Failed Stability Specifications; out of specification for shear.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 25, 2021. Severity: Moderate. Recall number: D-0724-2021.